Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06254768

Use of Continuous Glucose Monitors in Children and Adolescents With Obesity

To study if continuous glucose monitors are feasible for use in children and adolescents with obesity.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pediatric Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

10 year–21 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pediatric Endocrinology Division, University of California

Los Angeles, California, 90025, United States

Location status: Recruiting

Location contact

Sri Nikhita Chimatapu

CONTACT

[email protected]

917-741-4080

About this study

Various CGMs are approved by the U.S. Food and Drug Administration (FDA) for use in children and adults with diabetes. However, to date, little is known about how CGM technology can be integrated into weight management strategies for adolescents with obesity. No study to date has explored the effects of unblinded vs. blinded CGM use alone, without any other lifestyle modification recommendations. Thus, to address this question, this is a cross-over feasibility trial of blinded vs. unblinded CGM use in youth with obesity. This study hypothesizes that CGM will be a feasible and acceptable technology for youth with obesity, without diabetes, to utilize, and that access to daily glucose trends will facilitate positive changes in eating behavior and daily activity level compared to blinded CGM use. Thirty adolescents with obesity will be recruited into a six-week cross-over trial. All participants will be randomly assigned to either the blinded or unblinded group for three weeks. And then cross over to the other group for another three weeks. The primary endpoints are recruitment, retention, and adherence. While the secondary endpoints are glycemic variability, as captured on CGM, change in weight as an excess percentage of 95th percentile, sleep, dietary intake, physical activity, and eating behaviors.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 10-21 years BMI >95th percentile

Exclusion criteria

  • Previous diagnosis of Prader Willi Syndrome or hypothalamic obesity
  • Intellectual disability
  • Previous or planned bariatric surgery
  • Hemoglobin A1c >6.5 %
  • Current use of medication that impacts weight

Treatment and study plan

Continuous Glucose Monitor

Device

its a device used to measure glucose from interstitial fluids and provides feedback regarding the same every 5 minutes.

Primary outcomes

  1. Feasibility of continuous glucose monitor(CGM) use in children and adolescents with obesity

    Time frame: 6 weeks

    Investigator will measure this outcome using recruitment rate achieved each month for the duration of the study period as the number of participants screened per month over the number of participants consented.

Secondary outcomes

  1. To access the change in glycemic variability measured by CGMS in unblinded versus blinded periods through standard deviation of the mean.

    Time frame: 6 weeks

    Investigator will measure the effect of un-blinded CGM versus blinded use on glycemic variability measured by the Standard Deviation of the mean glycemia (SD) measured by CGMS.

Other outcomes

  1. Effect of on sleep in youth with obesity using CGMs

    Time frame: 6 weeks

    Investigator will assess the effect on quality of sleep in youth with obesity when using CGMs with the help of Pittsburgh Sleep Quality Index. The Pittsburgh Sleep Quality Index scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.

  2. Effect of CGM use on physical activity in youth with obesity when using CGMs

    Time frame: 6 weeks

    Investigator will assess the effect on physical activity when using CGMS with the help of International Physical Activity Questionnaire. The items on the form are structured to provide separate scores on walking, moderate-intensity and vigorous-intensity activity. Computation of the total score for the short form requires summation of the duration (in minutes) and frequency (days) of walking, moderate-intensity and vigorous-intensity activities.

  3. Effect of CGM use on dietary intake in youth with obesity when using CGMs

    Time frame: 6 weeks

    Investigator will assess the effect on dietary intake when using CGMS with the help of The Automated Self-Administered 24-hour Dietary Assessment Tool which is a tool that enables multiple, automatically coded, self-administered 24-hour diet recalls and/or single or multi-day food records, also known as food diaries.

  4. Effect of CGM use on eating behaviors in youth with obesity when using CGMs

    Time frame: 6 weeks

    Investigator will assess the effect on eating behaviors in youth with obesity when using CGMs with the help of Dutch Eating Behavior Questionnaire. Items on the Dutch Eating Behavior Questionnaire range from 1 (never) to 5 (very often), with higher scores indicating greater endorsement of the eating behavior.

  5. Effect of CGM use on change in the BMI as a percentage of the 95th percentile (%BMIp95) in youth with obesity when using CGMs

    Time frame: 6 weeks.

    Investigator will measure the change in the BMI as a percentage of the 95th percentile (%BMIp95) in youth with obesity when using CGMs between baseline to week 6.

Study contacts

Contact information is provided by the study sponsor or research team.

Sri Nikhita Chimatapu, MD

CONTACT

[email protected]

9177414080

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Registry information

Acronym: CGM

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Feb 12, 2024
Registry last updated
Feb 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.